This paper by Moritz Fürstenau, Michael Hallek and Barbara Eichhorst, per the recent post by avzuclav , provides a very readable overview of the current situation with respect to the challenges of continued monotherapy on Ibrutinib and subsequent investigations to determine the best multi-drug treatment approach.
We've had a bit of discussion on this topic recently, so I thought it would be worthwhile revisiting this paper, this time including the graphical illustration of the different novel drug CLL cell targets.
Here's the previous post, which includes an image of the summary table of the performance of the different novel agents alone and in combination: healthunlocked.com/cllsuppo...
It may well be that a personalised treatment approach will be the eventual outcome of this research. If so, finding a specialist that keeps across new developments and has a large number of CLL patients, will become even more important if you wish to avoid sub-optimal management and treatment.
There are a number of very important posts on Ibrutinib in the pinned posts section : healthunlocked.com/cllsuppo...
of which these are the most imporant:
healthunlocked.com/cllsuppo...
healthunlocked.com/cllsuppo...
healthunlocked.com/cllsuppo...
Image from Figure 1 of the referenced paper:
haematologica.org/content/e... Targets of currently approved (black) and investigated (gray) novel agents. BCR = B Cell Receptor. From Figure 1 in the referenced document,which was produced by M. Fürstnau using servier medical art (smart.servier.com)
This is an unlocked (discoverable via Internet search) post
Neil
Advances in drug‐based therapies in chronic lymphocytic leukemia and future prospects
